January 28, 2022 News by Marta Figueiredo, PhD Cortrophin Gel Now Widely Available in US for Acute Relapses ANI Pharmaceuticals has announced the full U.S. commercial availability of Cortrophin Gel (repository corticotropin injection), an injectable therapy approved for managing acute relapses in people with multiple sclerosis (MS) and other autoimmune disorders. āPatients with certain chronic autoimmune conditions often need additional treatment options,ā Mary Pao Seideman, MD,…
January 24, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: MRSI, Acthar Gel, Tecfidera vs. Gilenya, Exergames Imaging Brain Metabolites May Help Diagnose, Monitor MS Have you ever heard of magnetic resonance spectroscopic imaging, or MRSI? I hadn’t until I read this story. It’s a technique that in concept allows a radiologist to see metabolites in the brain. Metabolites are small molecules that are produced during…
January 19, 2022 News by Marisa Wexler, MS Acthar Gel May Help RRMS Patients Who Fail Corticosteroids Acthar Gel (repository corticotropin injection) may be useful for managing disease relapses in people with relapsing-remitting multiple sclerosis (RRMS) who fail to respond to treatment with corticosteroids, according to results from a small clinical trial. The study, “Results from a multicenter, randomized, double-blind, placebo-controlled study…
December 21, 2021 News by Margarida Maia, PhD Cortrophin Gel Now Available in US at AllianceRx Walgreens Prime Cortrophin Gel (repository corticotropin injection), an injectable gel medication approved for acute flares in multiple sclerosis (MS) and other chronic autoimmune diseases, is now available through the AllianceRx Walgreens Prime specialty pharmacy to patients living in the U.S. First approved by the U.S. Food and Drug Administration (FDA)…
December 20, 2021 Columns by Ed Tobias MS News That Caught My Eye Last Week: COVID-19 Vaccines, Achtar Gel, Ublituximab, Pregnancy Study: Anti-CD20 Therapies, Gilenya Lower Efficacy of COVID-19 Vaccines This research adds more evidence to studies that have already shown that certain disease-modifying therapies reduce the effectiveness of COVID-19 vaccines. Those DMTs include Kesimpta (ofatumumab) and Ocrevus (ocrelizumab), plus rituximab, another anti-CD20 vaccine, that is sometimes used…
December 16, 2021 News by Marisa Wexler, MS Little Evidence Acthar Gel Better Than Cheaper Substitutes: Review There is minimal evidence that the expensive anti-inflammatory medication Acthar Gel (repository corticotropin injection) is more effective than inexpensive corticosteroids for the treatment of multiple sclerosis (MS) and other diseases, according to a new review paper. “We found no evidence where it was a conclusive slam dunk that…
November 8, 2021 Columns by Ed Tobias MS News That Caught My Eye Last Week: Acthar Gel, Alcohol and MS Risk, Mindfulness Analysis Finds Acthar Gel Cost-effective for MS Relapses I’ve seen social media posts from people with MS who use Acthar Gel and report that it helps with their spasticity. The gel, which is a shot, not an ointment, prompts the body to creates cortisol, a steroid hormone that helps…
November 4, 2021 News by Margarida Maia, PhD Analysis Finds Acthar Gel Cost-effective for MS Relapses Acthar Gel (repository corticotropin injection) was found to be a cost-effective treatment for people with multiple sclerosis (MS) experiencing a relapse, according to an economic analysis. Notably, the economic value of Acthar Gel was greater than that of alternative treatments āĀ plasmapheresis and intravenous immunoglobulin ā from the…
November 2, 2021 News by Yedida Y Bogachkov PhD FDA Approves Reintroduced Cortrophin Gel for MS Exacerbations The injectable ACTH gel medication Cortrophin Gel (repository corticotropin injection), first introduced in the U.S. in the 1950s, will now be relaunched as a treatment for acute flare-ups in multiple sclerosis (MS) and other autoimmune conditions, following its approval by the U.S. Food and Drug Administration (FDA). In…
April 9, 2020 Columns by Tamara Sellman Need to Know: What Is Acthar Gel? Editor’s note: “Need to Knowā is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum post “MS Treatment Eases Flare-up Symptoms After 2 Months” from Oct.
March 27, 2020 News by Patricia Inacio, PhD Potential Competitor to Acthar Gel Asking to Re-enter US Market ANI Pharmaceuticals is asking the U.S. Food and Drug Administration (FDA) for the right to reintroduce in the U.S. market its Cortrophin Gel (repository corticotropin injection, 80 U/ml) to treat acute exacerbations in multiple sclerosis (MS) and other diseases. Currently, the only repository corticotropin injection available in…
March 2, 2020 News by Patricia Inacio, PhD #ACTRIMS2020 – Acthar Gel Ably Treats MS Relapses, Topline Data Show Acthar GelĀ (repository corticotropin injection) leads to significant improvements after two months of use in people with multiple sclerosis (MS) still having acute relapses despite treatment, and who failed to respond to other high-dose corticosteroids, topline data from an observational study show. The gel’s developer, Mallinckrodt Pharmaceuticals, also…
November 12, 2019 News by Ana Pena PhD Acthar Gel Quite Effective at Resolving Relapses as Alternative to Corticosteroids, Study Reports Acthar Gel (repository corticotropin injection) is more effective for treating flaresĀ inĀ multiple sclerosis (MS) than other alternatives, including intravenous immunoglobulin or plasmapheresis, a claims-based study from Mallinckrodt PharmaceuticalsĀ reports. The study “Treatment Effectiveness for Resolution of Multiple Sclerosis…
October 3, 2019 News by Joana Carvalho, PhD Acthar Gel Eases MS Flare-up Symptoms After Two Months of Treatment, Observational Study Shows Acthar Gel (repository corticotropin injection) eased flare-up symptoms in patients with multiple sclerosis (MS) experiencing relapses, top-line data from an observational registry study shows. Acthar Gel, a medication developed and marketed by Mallinckrodt Pharmaceuticals, is a compound that enhances the production of steroids in the…
September 23, 2019 Columns by Ed Tobias MS News that Caught My Eye Last Week: Ozanimod, Achtar Gel, Onset Age Progression Link, Glial Cells Could Differentiate MS Types In this column, I take a look at more exciting research from the ECTRIMS2019 conference this month. #ECTRIMS2019 ā Ozanimodās āKey Advantagesā May Lead to New First-line MS Therapy: Interview with Neurologist Jeffrey Cohen This year we’ve seen the approval of two new multiple sclerosis treatments in the United…
September 18, 2019 News by Patricia Inacio, PhD #ECTRIMS2019 – Acthar Gel Seen as Cost-effective Late-line Treatment Option for MS Relapses Late-line use ofĀ H.P. Acthar GelĀ to treat relapses in adults with multiple sclerosis (MS) is linked with lower costs than other therapies used after an initial poor response, including plasmapheresis and intravenous immunoglobulin, according to an analysis by Mallinckrodt Pharmaceuticals, the treatment’s marketer. George Wan, PhD, Mallinckrodt’sĀ vice president and…
June 5, 2017 Columns by Ed Tobias MS News That Caught My Eye: An Acne Drug, a High-Cost Gel, Good News About Lemtrada, and Getting Off MS Drugs In case you missedĀ them, here are some news stories that appeared in MS News Today that caught my eye over the past week. Acne Therapy Reduces Rate of Multiple Sclerosis Progression, Canadian Study Reports At first glance, the headlines about this drug announced what seemed to be…
June 1, 2017 News by Patricia Silva, PhD Mallinckrodt Enrolls First Patient in Acthar Gel Clinical Trial for Relapsing Multiple Sclerosis Mallinckrodt has enrolled its first relapsing multiple sclerosis (MS) patient into a Phase 4 clinical trial (NCT03126760) withĀ H.P. Acthar Gel (Repository Corticotropin Injection) to see if the therapyĀ can help treat relapse symptoms in patients who did not respond to high-dose steroids. If successful, the trial might resolve…
May 4, 2016 News by Patricia Silva, PhD Acthar Gel an Effective Treatment for MS Relapses at Lower Cost, Company Reports Clinical results presented at the recentĀ Academy of Managed Care Pharmacy (AMCP)‘s 2016 annual meetingĀ in San Francisco showed that the use of H.P. Acthar Gel during multiple sclerosis (MS) relapses is associated with beneficial outcomes.Ā The gel, according to its producer,Ā is also available at a lower price than other frequently used…